564 related articles for article (PubMed ID: 24184483)
1. Berberine slows cell growth in autosomal dominant polycystic kidney disease cells.
Bonon A; Mangolini A; Pinton P; Del Senno L; Aguiari G
Biochem Biophys Res Commun; 2013 Nov; 441(3):668-74. PubMed ID: 24184483
[TBL] [Abstract][Full Text] [Related]
2. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
3. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model.
Leonhard WN; van der Wal A; Novalic Z; Kunnen SJ; Gansevoort RT; Breuning MH; de Heer E; Peters DJ
Am J Physiol Renal Physiol; 2011 May; 300(5):F1193-202. PubMed ID: 21345977
[TBL] [Abstract][Full Text] [Related]
4. The regulatory 1α subunit of protein kinase A modulates renal cystogenesis.
Ye H; Wang X; Constans MM; Sussman CR; Chebib FT; Irazabal MV; Young WF; Harris PC; Kirschner LS; Torres VE
Am J Physiol Renal Physiol; 2017 Sep; 313(3):F677-F686. PubMed ID: 28615245
[TBL] [Abstract][Full Text] [Related]
5. The inhibition of MDM2 slows cell proliferation and activates apoptosis in ADPKD cell lines.
Patergnani S; Giattino A; Bianchi N; Giorgi C; Pinton P; Aguiari G
Biol Cell; 2023 Jan; 115(1):e2200037. PubMed ID: 36165233
[TBL] [Abstract][Full Text] [Related]
6. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1/cyclin axis.
Li A; Fan S; Xu Y; Meng J; Shen X; Mao J; Zhang L; Zhang X; Moeckel G; Wu D; Wu G; Liang C
J Cell Mol Med; 2017 Aug; 21(8):1619-1635. PubMed ID: 28244683
[TBL] [Abstract][Full Text] [Related]
8. Cell Proliferation and Apoptosis in ADPKD.
Lee EJ
Adv Exp Med Biol; 2016; 933():25-34. PubMed ID: 27730432
[TBL] [Abstract][Full Text] [Related]
9. TRPP2 dysfunction decreases ATP-evoked calcium, induces cell aggregation and stimulates proliferation in T lymphocytes.
Magistroni R; Mangolini A; Guzzo S; Testa F; Rapanà MR; Mignani R; Russo G; di Virgilio F; Aguiari G
BMC Nephrol; 2019 Sep; 20(1):355. PubMed ID: 31514750
[TBL] [Abstract][Full Text] [Related]
10. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
[TBL] [Abstract][Full Text] [Related]
12. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model.
Pastor-Soler NM; Li H; Pham J; Rivera D; Ho PY; Mancino V; Saitta B; Hallows KR
Am J Physiol Renal Physiol; 2022 Jan; 322(1):F27-F41. PubMed ID: 34806449
[TBL] [Abstract][Full Text] [Related]
13. Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease.
Chen L; Zhou X; Fan LX; Yao Y; Swenson-Fields KI; Gadjeva M; Wallace DP; Peters DJ; Yu A; Grantham JJ; Li X
J Clin Invest; 2015 Jun; 125(6):2399-412. PubMed ID: 25961459
[TBL] [Abstract][Full Text] [Related]
14. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
[TBL] [Abstract][Full Text] [Related]
15. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA501-5p induces p53 proteasome degradation through the activation of the mTOR/MDM2 pathway in ADPKD cells.
de Stephanis L; Mangolini A; Servello M; Harris PC; Dell'Atti L; Pinton P; Aguiari G
J Cell Physiol; 2018 Sep; 233(9):6911-6924. PubMed ID: 29323708
[TBL] [Abstract][Full Text] [Related]
17. Human polycystin-2 transgene dose-dependently rescues ADPKD phenotypes in Pkd2 mutant mice.
Li A; Tian X; Zhang X; Huang S; Ma Y; Wu D; Moeckel G; Somlo S; Wu G
Am J Pathol; 2015 Oct; 185(10):2843-60. PubMed ID: 26435415
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
Liu Y; Dai B; Fu L; Jia J; Mei C
Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
Bastos AP; Onuchic LF
Braz J Med Biol Res; 2011 Jul; 44(7):606-17. PubMed ID: 21625823
[TBL] [Abstract][Full Text] [Related]
20. Divergent function of polycystin 1 and polycystin 2 in cell size regulation.
Viau A; Kotsis F; Boehlke C; Braeg S; Klein M; Nitschke R; Walz G; Kuehn EW
Biochem Biophys Res Commun; 2020 Jan; 521(2):290-295. PubMed ID: 31668373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
